Remove 2007 Remove Diabetes Remove Labelling
article thumbnail

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

pharmaphorum

The approval comes a few weeks after the biosimilar was cleared for marketing in the EU with a broader label, as it also includes diabetic macular oedema (DMO), another of Lucentis’ approved indications. Sales reached a peak in 2019, when Roche booked $1.8 billion in sales from the drug while Novartis made $2.1 billion and $1.9

article thumbnail

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

Byooviz launched on 1 July at a 40% discount to Lucentis, with a label that covers use of the biosimilar for wet age-related macular degeneration (AMD), macular oedema following retinal vein occlusion (RVO), and myopic choroidal neovascularisation. Roche has US marketing rights to the drug, and booked $1.3

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Japan’s M&A Boom

Pharmaceutical Technology

“The business integration from 2005 to 2007 of the two separate companies to form the joint Daiichi Sankyo created one of Japan’s biggest pharmaceutical companies.” Like in many other sectors, China and India are the ones labelled as those which will lead the expansion. % increase over the previous year.

article thumbnail

NHC Submits Comments on CMS Draft Guidance for IPAY 2028

Putting Patients First Blog

This step would ensure that real-world considerations, such as off-label uses and quality-of-life impacts, are factored into revised pricing decisions. 1 (July 4, 2007): 61– 69, [link] 48 U.S. A minimum 60-day window for public input should be established, with outreach to affected patient groups. Goldman, Geoffrey F.

article thumbnail

NHC Submits Comments to CMS RE CY 2026 Policy & Technical Changes to MA and Part D Proposed Rule

Putting Patients First Blog

3 ,4, 5 As such, the NHC supports CMS proposal to ensure that Part D sponsors cover AOMs for obesity with clinical criteria that is not more restrictive than the FDA labeling for each AOM. 2 (April 2007): 644662, [link] 6773.2006.00626.x. 29 Julia C. Prentice and Steven D. 1 (2020): 1624, [link] 31 U.S.

article thumbnail

Air Quality and Hashimoto’s – Is the Air You’re Breathing Making You Sick?

The Thyroid Pharmacist

Perhaps more concerning, of the 133 different VOCs found across all tested products, only one, ethanol, was actually listed on any label! (13, For sunscreens and other over-the-counter drugs, fragrances must be identified on the label. But formaldehyde has been labeled as a known human carcinogen by the U.S. Accessed April 2022.

article thumbnail

Five Things For Pharmacists To Know About The Treatment Of Mycobacterium Tuberculosis

ID Stewardship

Antimicrob Agents Chemother 2007; 51:3781–8. Her postgraduate education includes an MSc in Pharmacy Practice, which focuses on unintended consequences of spurious penicillin allergy labels, non-medical independent prescribing, and a healthcare leadership fellowship. 6. Gumbo T, Louie A, Deziel MR, et al. 7. Jindani, G.